MARKET

ALDX

ALDX

Aldeyra
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.05
-0.01
-0.20%
After Hours: 5.05 0 0.00% 16:12 02/21 EST
OPEN
5.07
PREV CLOSE
5.06
HIGH
5.10
LOW
5.03
VOLUME
119.72K
TURNOVER
--
52 WEEK HIGH
12.79
52 WEEK LOW
4.310
MARKET CAP
141.16M
P/E (TTM)
-2.3304
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ALDX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ALDX stock price target is 27.71 with a high estimate of 34.00 and a low estimate of 20.00.

EPS

ALDX News

More
  • Aldeyra Therapeutics to Host 2020 Research & Development Day
  • Business Wire · 02/11 13:00
  • Aldeyra Therapeutics Appoints Dr. Paul Karpecki to Anterior Segment Scientific Advisory Board
  • Business Wire · 01/28 13:00
  • Aldeyra commences late-stage study of reproxalap in allergic conjunctivitis
  • seekingalpha · 01/21 18:26
  • Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 INVIGORATE Trial in Allergic Conjunctivitis
  • Business Wire · 01/21 13:00

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About ALDX

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.
More

Webull offers kinds of Aldeyra Therapeutics Inc stock information, including NASDAQ:ALDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALDX stock news, and many more online research tools to help you make informed decisions.